ALKBH5 was upregulated in primary non-small-cell lung cancer (NSCLC) tissues, positively correlating with macrophage infiltration and programmed death-ligand 1 (PD-L1) expression, suggesting that ALKBH5 enhances susceptibility to anti-PD-L1 therapy in NSCLC [16]. The gene discussed is ALKBH5; the disease is non-small cell lung carcinoma.